Galmed Pharmaceuticals (GLMD) Expected to Post Earnings on Thursday

Galmed Pharmaceuticals (NASDAQ:GLMD) will likely be posting its results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter.

Galmed Pharmaceuticals Trading Up 2.7%

Galmed Pharmaceuticals stock opened at $0.53 on Tuesday. The firm has a market capitalization of $2.89 million, a P/E ratio of -0.58 and a beta of 0.75. Galmed Pharmaceuticals has a twelve month low of $0.41 and a twelve month high of $2.03. The stock’s fifty day simple moving average is $0.58 and its 200-day simple moving average is $0.63.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Galmed Pharmaceuticals stock. Two Sigma Investments LP acquired a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned approximately 1.28% of Galmed Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.